The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study

BACKGROUND: Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. METHODS: To obtain an objective efficacy report of different real‐world treatment models of osimertinib and antiangiogenic agents....

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yu, Huang, Liling, Zhu, Haohua, Tang, Le, Hu, Xingsheng, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475224/
https://www.ncbi.nlm.nih.gov/pubmed/36082809
http://dx.doi.org/10.1111/1759-7714.14603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475224/
https://www.ncbi.nlm.nih.gov/pubmed/36082809
http://dx.doi.org/10.1111/1759-7714.14603

Ejemplares similares